Inflammatory Bowel Disease

Among patients with Crohn’s disease, achieving a sustained clinical remission off steroids with complete endoscopic remission did not correlate with less disease progression, according to study results.

The body of knowledge around the COVID-19 pandemic is fast moving and always expanding. Fortunately, in most parts of the country, the recent “delta wave” seems to be subsiding. However, our patients still have many questions about COVID, especially around the topic of vaccination. This month’s cover story focuses on the need for an additional dose of vaccine.

Immunocompromised individuals have several justifiable concerns surrounding COVID-19. One of those concerns is that a two-dose vaccine schedule may not produce a sufficient antibody response to protect them from the virus.

Using a novel clinical pathway integrated into the electronic medical record, researchers were able to identify patients with inflammatory bowel disease who were overdue for medical follow-ups, according to data presented at the ACG Annual Scientific Meeting.

Treatment preferences varied widely among patients with inflammatory bowel disease but were largely influenced by a desire for reduction in abdominal pain, according to data from the P-POWER IBD study presented at the ACG Annual Scientific Meeting.

Factors such as race, political affiliation and income played a greater role than disease-related attributes in vaccine hesitancy of patients with inflammatory bowel disease, according to a presentation at the ACG Annual Scientific Meeting.

In a commentary published in Gastroenterology, experts propose initiatives that aim to increase diversity in inflammatory bowel disease clinical trials.

Using real-world data, researchers identified patterns of use of medically dispensed cannabis in patients with inflammatory bowel disease, according to a poster presented at the ACG Annual Scientific Meeting.

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

Adults with inflammatory bowel disease produced strong antibody responses to messenger RNA COVID-19 vaccines, according to findings published in Annals of Internal Medicine.